tldrdailynews.com logo

Teva's IL-15 antibody shows phase 2a promise in celiac disease

1 min read
Source: Fierce Biotech
Teva's IL-15 antibody shows phase 2a promise in celiac disease
Photo: Fierce Biotech
TL;DR Summary

Teva's anti-IL-15 antibody TEV '408 beat placebo in a phase 2a celiac trial, reducing gluten-induced intestinal damage in 50 adults with no safety signals, paving the way for phase 3 pending further analysis; the program also spans vitiligo, with broader IL-15–axis potential in autoimmune diseases.

Topics:business#autoimmune-disease#celiac-disease#healthcare#il-15#phase-2#teva
Share this article
  1. Teva autoimmune antibody notches ph. 2 win in celiac disease  Fierce Biotech
  2. Teva’s immune disorder drug meets main goal in mid-stage trial  WKZO
  3. Why is Teva Pharma stock surging today?  Investing.com India
  4. Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute  Yahoo Finance
  5. Teva's immune disorder drug meets main goal in mid-stage trial  tradingview.com

Reading Insights

Total Reads

0

Unique Readers

3

Time Saved

2 min

vs 3 min read

Condensed

91%

502 → 45 words

Want the full story? Read the original article

Read on Fierce Biotech